BEGIN:VCALENDAR VERSION:2.0 PRODID:-//app.ishl.eu//Schedule X-WR-CALNAME:ISHL10 CALSCALE:GREGORIAN BEGIN:VTIMEZONE TZID:Europe/Berlin TZURL:http://tzurl.org/zoneinfo-outlook/Europe/Berlin X-LIC-LOCATION:Europe/Berlin BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:19700329T020000 RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=-1SU END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:19701025T030000 RRULE:FREQ=YEARLY;BYMONTH=10;BYDAY=-1SU END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-1@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161022T083000 DTEND;TZID=Europe/Berlin:20161022T120000 SUMMARY:Hematology Educational - Hematology Educational LOCATION:Großer Saal DESCRIPTION:Talks: Introduction, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), Aggressive Non-Hodgkin Lymphoma, Coffee break, Follicular Lymphoma (FL), Multiple Myeloma (MM) X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Hematology Educational - Hematology Educational ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-2@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161022T090000 DTEND;TZID=Europe/Berlin:20161022T103000 SUMMARY:Workshop 1 - New Concepts of Radiation Field Design, Advanced Technologies and New Normal Organ Constraints LOCATION:Isabellensaal DESCRIPTION:Talks: Radiation eld reduction beyond ISRT? – options and concerns, Avoidance of organs at risk / dose-volume constraints – deep inspiration breath hold: techniques and daily monitoring, Avoidance of organs at risk / dose-volume constraints – dose / volume constrains for key organs at risk X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 1 - New Concepts of Radiation Field Design, Advanced Technologies and New Normal Organ Constraints ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-3@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161022T090000 DTEND;TZID=Europe/Berlin:20161022T103000 SUMMARY:Workshop 2 - Epidemiology and Registry Data LOCATION:Kleiner Saal DESCRIPTION:Talks: Welcome and short introduction, Experience from the international T cell project, Registry studies on Hodgkin Lymphoma – the US experience, Registry-based studies on socio-economic impact on outcome in Hodgkin Lymphoma in Brazil, Registry-based studies on pregnancy in Hodgkin Lymphoma patients, Registry-based research – pros and cons – the statistician’s view, General discussion X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 2 - Epidemiology and Registry Data ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-4@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161022T104500 DTEND;TZID=Europe/Berlin:20161022T121500 SUMMARY:Workshop 3 - Pathology and Pathogenesis LOCATION:Isabellensaal DESCRIPTION:Talks: Risk and prognosis in Hodgkin Lymphoma and associations with an active, innate or anergic tumor immune response, NF-KB / IRF5 in Hodgkin Lymphoma, Noncoding RNAs and microRNA in Hodgkin Lymphoma X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 3 - Pathology and Pathogenesis ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-5@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161022T104500 DTEND;TZID=Europe/Berlin:20161022T121500 SUMMARY:Workshop 4 - PET LOCATION:Kleiner Saal DESCRIPTION:Talks: Pretreatment stage or metabolic volume: which is better to direct treatment strategy?, Response assessment in the era of checkpoint inhibitors X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 4 - PET ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-6@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161022T124500 DTEND;TZID=Europe/Berlin:20161022T134500 SUMMARY:Satellite Symposium - Recent Advances in the Treatment of Lymphoma LOCATION:Großer Saal DESCRIPTION:Talks: The FLASH project: establishing a novel surrogate endpoint in first-line FL, Update on clinical data of IMiDs® in the treatment of lymphoma X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - Recent Advances in the Treatment of Lymphoma ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-7@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161022T140000 DTEND;TZID=Europe/Berlin:20161022T153000 SUMMARY:Workshop 5 - Biomarkers LOCATION:Großer Saal DESCRIPTION:Talks: Methodological issues of circulating cell-free DNA detection in HL, Outcome prediction of aSCT using Hodgkin Lymphoma relapse biopsies, Nanostring-based outcome prediction in HL patients treated with BEACOPP, Integration of IPS factors with gene expression for treatment outcome prediction, Biomarkers / companion diagnostics for checkpoint inhibition X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 5 - Biomarkers ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-8@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161022T140000 DTEND;TZID=Europe/Berlin:20161022T153000 SUMMARY:Workshop 6 - Elderly Patients LOCATION:Kleiner Saal DESCRIPTION:Talks: US experience in elderly HL, European experience in elderly HL, Geriatric assessment, Trials on Brentuximab Vedotin and checkpoint inhibitors in elderly HL, Population based data on elderly HL X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 6 - Elderly Patients ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-9@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161022T140000 DTEND;TZID=Europe/Berlin:20161022T153000 SUMMARY:Workshop 7 - GHSG Workshop LOCATION:Isabellensaal DESCRIPTION: X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 7 - GHSG Workshop ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-10@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161022T160000 DTEND;TZID=Europe/Berlin:20161022T173000 SUMMARY:Workshop 8 - Genetics and Microenvironment LOCATION:Großer Saal DESCRIPTION:Talks: Molecular pathogenesis of NLPHL, The B cell receptor speci city of LP cells in NLPHL, Hodgkin cell-derived extracellular vesicles shape broblast activity, The lymphoid cell speci c transcription factor ELF-1 is downregulated and deleted in classical Hodgkin lymphoma, Tightly regulated FOXO3 expression is critical for the maintenance of cHL X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 8 - Genetics and Microenvironment ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-11@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161022T160000 DTEND;TZID=Europe/Berlin:20161022T173000 SUMMARY:Workshop 9 - NLPHL LOCATION:Isabellensaal DESCRIPTION:Talks: Update on classi cation of NLPHL and its distinction from TCRBCL and transformed DLBCL, Latest GHSG data on NLPHL, Case studies of patients with “apparent” relapse of NLPHL X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 9 - NLPHL ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-12@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161022T160000 DTEND;TZID=Europe/Berlin:20161022T173000 SUMMARY:Workshop 10 - Late Effects LOCATION:Kleiner Saal DESCRIPTION:Talks: Influence of radiotherapy and chemotherapy in modern Hodgkin Lymphoma treatment on risks of cardiovascular disease and second malignancy, Reducing cardiovascular risk in Hodgkin Lymphoma survivors – the SECURE trial, Phase 2 trial comparing the feasibility and efficacy of physical activity and multifactorial drug treatment in Hodgkin Lymphoma survivors X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 10 - Late Effects ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-13@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161022T174500 DTEND;TZID=Europe/Berlin:20161022T191500 SUMMARY:Satellite Symposium - Into the Future – New Treatment Options for Hematologic Malignancies LOCATION:Großer Saal DESCRIPTION:Talks: Welcome, Midostaurin – a novel therapeutic approach for patients with FLT3-mutated AML, The concept of treatment-free remission in CML – results from current studies, Panobinostat for relapsed or refractory myeloma: pan-HDAC-inhibition with epigenetic e ects, Advances in the treatment of hematologic malignancies: use of CAR T cells X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - Into the Future – New Treatment Options for Hematologic Malignancies ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-14@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161023T073000 DTEND;TZID=Europe/Berlin:20161023T083000 SUMMARY:Satellite Symposium - The Evolution of Chemotherapy: Using the A-DAC Principle to Unlock New Treatment Options in Hodgkin Lymphoma LOCATION:Großer Saal DESCRIPTION:Talks: The evolution of chemotherapy – an introduction from the chair, The A-DAC principle – introducing EDO-S101, Breaking through resistance – the potential for EDO-S101 (an overview of pre-clinical data in Hodgkin Lymphoma), EDO-S101: pre-clinical data in Multiple Myeloma and initial ndings from phase I in haematological malignancies, Unlocking the potential – Q&A session X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - The Evolution of Chemotherapy: Using the A-DAC Principle to Unlock New Treatment Options in Hodgkin Lymphoma ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-15@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161023T083000 DTEND;TZID=Europe/Berlin:20161023T100000 SUMMARY:Scientific Session 1 - Interactive Case Discussions LOCATION:Großer Saal DESCRIPTION:Talks: Case Discussion #1: Early Unfavorable - PET driven?, Case Discussion #2: HL during pregnancy, Case Discussion #3: Late Relapse of HL, Case Discussion #4: Relapsed/Refractory HL and PD-1i X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 1 - Interactive Case Discussions ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-16@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161023T103000 DTEND;TZID=Europe/Berlin:20161023T120000 SUMMARY:Scientific Session 2 - MRD and Prediction LOCATION:Großer Saal DESCRIPTION:Talks: Clinical – IPS and other scores, Serum marker, Circulating cell-free DNA in HL, Plasma vesicle-associated miRNAs as therapy response biomarkers in Hodgkin Lymphoma, Mid-treatment TARC and mid-treatment FDG-PET predict for progression free survival in classical Hodgkin Lymphoma, A comprehensive analysis of Hodgkin Lymphoma seasonality across various geographic regions X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 2 - MRD and Prediction ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-17@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161023T121500 DTEND;TZID=Europe/Berlin:20161023T134500 SUMMARY:Satellite Symposium - New Insights in the Treatment and Management of Lymphoid Malignancies LOCATION:Großer Saal DESCRIPTION:Talks: Welcome, Impact of febrile neutropenia in the HD18 trial: nal analysis of the project “daily G-CSF versus Peg lgrastim”, BiTE®: a new strategy for hematologic malignancies, Multiple Myeloma: new treatment options for patients with Car lzomib, Conclusion and closing remarks X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - New Insights in the Treatment and Management of Lymphoid Malignancies ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-18@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161023T140000 DTEND;TZID=Europe/Berlin:20161023T153000 SUMMARY:Workshop 11 - Immunomodulation LOCATION:Kleiner Saal DESCRIPTION:Talks: Biological basis for PD-1 based immunotherapy, How do we rationally combine immune checkpoint therapy for optimal impact, Radiotherapy and immunotherapy combinations, Allo transplant vs checkpoint blockade in HL X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 11 - Immunomodulation ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-19@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161023T140000 DTEND;TZID=Europe/Berlin:20161023T153000 SUMMARY:Workshop 12 - Current Concepts in Allo TX LOCATION:Großer Saal DESCRIPTION:Talks: Allo-SCT in RR HL. The state of the art, The impact of the stem cell source (HLA id Sib vs MUD vs CB vs Haplo) in the outcome after allo-SCT, The role of allogeneic stem cell transplantation in the era of new drugs X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 12 - Current Concepts in Allo TX ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-20@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161023T140000 DTEND;TZID=Europe/Berlin:20161023T153000 SUMMARY:Workshop 13 - Grey Zone Lymphoma LOCATION:Marsilius Saal DESCRIPTION:Talks: Pathology of grey zone lymphomas, Joint pediatric Hodgkin and Non-Hodgkin lymphoma study group on grey zone lymphoma in children and adolescents, Retrospective study of grey zone lymphomas, Mediastinal grey zone lymphomas: are they more like PMBL or nsHL? X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 13 - Grey Zone Lymphoma ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-21@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161023T160000 DTEND;TZID=Europe/Berlin:20161023T173000 SUMMARY:Satellite Symposium - Relapsed / Refractory Hodgkin Lymphoma: Nuances in Therapeutic Strategies to Improve Outcomes – a Case-Based Program LOCATION:Großer Saal DESCRIPTION:Talks: Welcome and introduction, Avoiding relapse of Hodgkin Lymphoma (HL): have we moved the needle?, Case #1: patient with advanced HL who relapses 18 months after initial therapy, Relapsed / refractory HL: therapeutic options prior to autologous stem cell transplant (ASCT), Case #2: patient with bulky relapsed HL occurring 10 months following initial therapy, Post-ASCT relapse: making the most of what we have, Q&A, Case #3: patient with HL who has relapsed following ASCT, Novel agents in HL: what, how, and when should they be integrated?, Challenge the experts, prIME PointsTM X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - Relapsed / Refractory Hodgkin Lymphoma: Nuances in Therapeutic Strategies to Improve Outcomes – a Case-Based Program ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-22@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161023T174500 DTEND;TZID=Europe/Berlin:20161023T194500 SUMMARY:Main Program - Opening Ceremony LOCATION:Großer Saal DESCRIPTION:Talks: Movie: A History of Hodgkin Lymphoma, Key Note Lectue, Awards Ceremony X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Main Program - Opening Ceremony ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-23@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161023T200000 SUMMARY:Main Program - Get Together LOCATION:Kleiner Saal DESCRIPTION: X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Main Program - Get Together ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-24@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161024T073000 DTEND;TZID=Europe/Berlin:20161024T083000 SUMMARY:Satellite Symposium - Future Directions in Lymphoma and Myeloma Therapy LOCATION:Großer Saal DESCRIPTION:Talks: Mode of action of PD1 / PD-L1 monoclonal antibodies in HL, Novel therapeutic strategies to improve outcome of patients with aggressive lymphomas, Targeting CD38 in Multiple Myeloma X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - Future Directions in Lymphoma and Myeloma Therapy ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-25@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161024T083000 DTEND;TZID=Europe/Berlin:20161024T100000 SUMMARY:Scientific Session 3 - Biology and Microenvironment LOCATION:Großer Saal DESCRIPTION:Talks: Genetic lesions in HRS cells and their relationship to CD30+ B cells, Exome-sequencing in HL, Gene expression pro ling of the HL microenvironment, Analysis of the mutational landscape and dynamics in Hodgkin Lymphoma using NGS, High expression of programmed cell death receptor 1 (PD-1) in the tumor microenvironment is associated with inferior event free survival in classical Hodgkin Lymphoma, The AP-1 transcription factor BATF3 regulates MYC expression and is required for tumor cell survival in classical Hodgkin Lymphoma and anaplastic large cell lymphoma X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 3 - Biology and Microenvironment ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-26@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161024T103000 DTEND;TZID=Europe/Berlin:20161024T120000 SUMMARY:Scientific Session 4 - Immunotherapy (Basic Science) LOCATION:Großer Saal DESCRIPTION:Talks: PD1 / PD-L1 / L2 assessment in HL, Mode of action of PD1 / PD-L1 MoAbs in HL, Other new approaches, Hodgkin Lymphoma infiltrating T cells: considering various means of tumor evasion, CCR5 blocking by Maraviroc inhibited recruitment, proliferation and pro- tumor e ects of mesenchymal stromal cells and monocytes in 2D and 3D models of Hodgkin Lymphoma microenvironment, Disturbed antigen presentation in classical Hodgkin Lymphoma: implications for immune checkpoint inhibitor therapy? X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 4 - Immunotherapy (Basic Science) ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-27@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161024T121500 DTEND;TZID=Europe/Berlin:20161024T134500 SUMMARY:Satellite Symposium - Evolving Therapy in the HL Treatment Landscape LOCATION:Großer Saal DESCRIPTION:Talks: Welcome and introductions, Rationale for I-O therapies in solid and hematological malignancies, Balancing the risk-benefit ratio: current treatment regimens and unmet needs in HL, I-O in cHL: an eye towards the future, Audience Q&A session conclusions X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - Evolving Therapy in the HL Treatment Landscape ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-28@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161024T140000 DTEND;TZID=Europe/Berlin:20161024T153000 SUMMARY:Scientific Session 5 - PET – Where Are We? LOCATION:Großer Saal DESCRIPTION:Talks: PET update 2016, WS report “Is PET as good as we think?”, Visual and quantitative PET / CT, Only focal bone marrow FDG uptake in baseline FDG-PET scan has a diagnostic and prognostic impact in Hodgkin Lymphoma: results from an international collaborative study, Strong predictive value of PET based metabolic tumor volume on survival after autologous HCT for Hodgkin Lymphoma, Semi-quantitative parameters to improve the interim FDG-PET / CT positive predictive value in Hodgkin Lymphoma X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 5 - PET – Where Are We? ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-29@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161024T160000 DTEND;TZID=Europe/Berlin:20161024T173000 SUMMARY:Scientific Session 6 - Early Stages LOCATION:Großer Saal DESCRIPTION:Talks: Early favorable HL: pros and cons of PET-adapted therapy, Early unfavorable: new standard of care?, NLPHL, Long-term follow-up of contemporary treatment in early-stage favorable Hodgkin Lymphoma (HL): updated analyses of the German Hodgkin Study Group HD7 and HD10 trial, Proton radiotherapy for mediastinal Hodgkin Lymphoma: single institution experience, Results of US intergroup trial of response-adapted chemotherapy or chemotherapy / radiation therapy based on PET for non-bulky stage I and II Hodgkin Lymphoma (HL) (CALGB / Alliance 50604) X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 6 - Early Stages ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-30@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161024T174500 DTEND;TZID=Europe/Berlin:20161024T191500 SUMMARY:Satellite Symposium - Managing Hodgkin Lymphoma – A World View LOCATION:Großer Saal DESCRIPTION:Talks: Welcome and introduction, Diagnostics in practice: the ideal and the pragmatic, Prognostic indicators in front-line HL: a practical guide to individualizing therapy, Imaging and monitoring strategies: optimizing available resources, Optimizing HL management in the relapsed / refractory setting: making the most of available options, Concluding remarks X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - Managing Hodgkin Lymphoma – A World View ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-31@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161025T073000 DTEND;TZID=Europe/Berlin:20161025T083000 SUMMARY:Satellite Symposium - Ask the Expert: An Open Forum on Hodgkin Lymphoma LOCATION:Großer Saal DESCRIPTION:Talks: Panelists X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - Ask the Expert: An Open Forum on Hodgkin Lymphoma ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-32@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161025T083000 DTEND;TZID=Europe/Berlin:20161025T100000 SUMMARY:Scientific Session 7 - Pediatric HL LOCATION:Großer Saal DESCRIPTION:Talks: Interim results of EuroNet-PHL-C1, Targeted agents in pediatric HL, COG / ECOG: AYA HL, Whole body functional and anatomical MRI: accuracy in staging and treatment response monitoring in childhood and adolescent Hodgkin’s Lymphoma compared to conventional multimodality imaging (CRUK C23580/ A12707), Phase III ABC study of response adapted therapy for the treatment of children with newly diagnosed very high risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): a report from the Children's Oncology Group, Outcomes in adolescents and young adults (AYA) with Hodgkin Lymphoma (HL) treated on US cooperative group protocols: an adult intergroup (E2496) and Children’s Oncology Group (COG AHOD0031) comparative analysis X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 7 - Pediatric HL ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-33@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161025T103000 DTEND;TZID=Europe/Berlin:20161025T120000 SUMMARY:Scientific Session 8 - Advanced Stages LOCATION:Großer Saal DESCRIPTION:Talks: Debate: PET-guided ABVD versus old school BEACOPP, Perspectives in advanced HL, BEACOPPescalated followed by radiotherapy of initial bulk or residual disease in advanced-stage Hodgkin Lymphoma: long-term follow-up of the GHSG HD9 and HD12 trials, Overall survival (OS) impact of BEACOPP versus ABVD in advanced Hodgkin Lymphoma: a pooled analysis of 4 randomized trials, Long-term follow-up of SWOG S0816: response-adapted therapy of advanced stage Hodgkin Lymphoma using early interim FDG-PET imaging, X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 8 - Advanced Stages ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-34@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161025T121500 DTEND;TZID=Europe/Berlin:20161025T130000 SUMMARY:Satellite Symposium - Classification of New Therapeutic Options for CLL and Follicular NHL LOCATION:Großer Saal DESCRIPTION:Talks: Chronic Lymphocytic Leukemia, Relapsed Follicular Non-Hodgkin Lymphoma X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - Classification of New Therapeutic Options for CLL and Follicular NHL ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-35@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161025T130000 DTEND;TZID=Europe/Berlin:20161025T134500 SUMMARY:Main Program - Poster Walk LOCATION:Kleiner Saal DESCRIPTION: X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Main Program - Poster Walk ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-36@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161025T140000 DTEND;TZID=Europe/Berlin:20161025T153000 SUMMARY:Scientific Session 9 - Relapsed HL LOCATION:Großer Saal DESCRIPTION:Talks: Brentuximab vedotin in relapsed HL, Clinical results with anti-PD(L)1 antibodies in HL, Role of allo-Tx in the PD1 era, CheckMate 205 cohort C: Nivolumab in patients with classical Hodgkin Lymphoma after prior Brentuximab Vedotin and autologous hematopoietic stem cell transplantation, Pembrolizumab for relapsed / refractory classical Hodgkin Lymphoma (R / R cHL): multicohort, phase 2 KEYNOTE-087 study, TRANSPLANT BRaVE: combining Brentuximab Vedotin with DHAP as salvage treatment in relapsed / refractory Hodgkin Lymphoma (HL). A phase 1 dose- escalation study X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 9 - Relapsed HL ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-37@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161025T160000 DTEND;TZID=Europe/Berlin:20161025T173000 SUMMARY:Scientific Session 10 - Survivorship LOCATION:Großer Saal DESCRIPTION:Talks: Fatigue, Survivorship surveillance, Second malignancies, Patient preferences – survey of HL survivors on treatment associated burdens and side effects, Change in peripheral blood lymphocyte telomere length in relation to mortality and morbidity in Hodgkin Lymphoma patients, The impact of treatment type and age on ovarian toxicity in the RATHL study X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 10 - Survivorship ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260716T034000 UID:session-38@app.ishl.eu/2016 DTSTART;TZID=Europe/Berlin:20161025T174500 SUMMARY:Scientific Session 11 - Closing Remarks LOCATION:Großer Saal DESCRIPTION: X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 11 - Closing Remarks ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT END:VCALENDAR